Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD)[1].
The simultaneous binding of Ordesekimab (AMG 714) to the Fcγ receptor (R) IIIα expressed on natural killer (NK) cells and to the IL-15/IL-15Rα complex on cells such as monocytes may theoretically enable antibody-dependent cell-mediated cytotoxicity (ADCC) toward the IL-15Rα-expressing cells[1].
[1]. Yu-Ling Wei, et al. Strategies to evaluate potential effector function of glycan variants: a case study of ordesekimab (AMG 714 or PRV-015). J Immunotoxicol. 2022 Dec;19(1):109-116.